These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 35875370)

  • 41. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action.
    Irwin MN; VandenBerg A
    Ment Health Clin; 2021 May; 11(3):200-210. PubMed ID: 34026396
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ketamine for Treatment-Resistant Mood Disorders.
    Park LT; Falodun TB; Zarate CA
    Focus (Am Psychiatr Publ); 2019 Jan; 17(1):8-12. PubMed ID: 31975953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical pharmacological innovation in the treatment of depression.
    Witkin JM; Golani LK; Smith JL
    Expert Rev Clin Pharmacol; 2023 Apr; 16(4):349-362. PubMed ID: 37000975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders.
    Lewis V; Rodrigue B; Arsenault E; Zhang M; Taghavi-Abkuh FF; Silva WCC; Myers M; Matta-Camacho E; Aguilar-Valles A
    J Neurochem; 2023 Jul; 166(1):10-23. PubMed ID: 35680556
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects.
    Sachdeva B; Sachdeva P; Ghosh S; Ahmad F; Sinha JK
    Ibrain; 2023; 9(1):90-101. PubMed ID: 37786516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Antidepressant-Like Effects of a Clinically Relevant Dose of Ketamine Are Accompanied by Biphasic Alterations in Working Memory in the Wistar Kyoto Rat Model of Depression.
    McDonnell CW; Dunphy-Doherty F; Rouine J; Bianchi M; Upton N; Sokolowska E; Prenderville JA
    Front Psychiatry; 2020; 11():599588. PubMed ID: 33551869
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
    Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral Ketamine for Depression: A Systematic Review.
    Rosenblat JD; Carvalho AF; Li M; Lee Y; Subramanieapillai M; McIntyre RS
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 30995364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of esketamine and treatment expectation in acute major depressive disorder (Expect): study protocol for a pharmacological fMRI study using a balanced placebo design.
    Falkenberg I; Bitsch F; Liu W; Matsingos A; Noor L; Vogelbacher C; Yildiz C; Kircher T
    Trials; 2023 Aug; 24(1):514. PubMed ID: 37568215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized placebo-controlled PET study of ketamine´s effect on serotonin
    Tiger M; Veldman ER; Ekman CJ; Halldin C; Svenningsson P; Lundberg J
    Transl Psychiatry; 2020 Jun; 10(1):159. PubMed ID: 32475989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
    Wei Y; Chang L; Hashimoto K
    Mol Psychiatry; 2022 Jan; 27(1):559-573. PubMed ID: 33963284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital.
    Gutierrez G; Kang MJY; Vazquez G
    Psychiatry Res; 2024 May; 335():115865. PubMed ID: 38518518
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2004; 4(7):1-98. PubMed ID: 23074457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression.
    Włodarczyk A; Cubała WJ; Gałuszko-Węgielnik M; Szarmach J
    Ther Adv Psychopharmacol; 2021; 11():20451253211011021. PubMed ID: 34046159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants.
    Browne CA; Lucki I
    Front Pharmacol; 2013 Dec; 4():161. PubMed ID: 24409146
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic ablation of the isoform γ of PI3K decreases antidepressant efficacy of ketamine in male mice.
    Vaz GN; Turcato FC; Lima IAV; Scarante FF; Araújo MR; Brigante TAV; Rodrigues LCM; Guimarães FS; Hallak JEC; Crippa JA; Teixeira AL; de Oliveira ACP; Campos AC
    IBRO Neurosci Rep; 2024 Dec; 17():87-95. PubMed ID: 39026898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New investigational agents for the treatment of major depressive disorder.
    Pochwat B; Krupa AJ; Siwek M; Szewczyk B
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1053-1066. PubMed ID: 35975761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.